Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2023-04-20 Board/Management Inform…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
List Prezesa Zarządu
Board/Management Information Classification · 99% confidence The document text begins with "Raport LIST PREZESA ZARZĄDU Szanowni Państwo, Drodzy Akcjonariusze, Przekazujemy Państwu raport roczny PolTREG S.A. za 2022 rok." (Report of the CEO to Shareholders, We present to you the annual report of PolTREG S.A. for 2022). This clearly indicates the document is the company's annual report for the fiscal year 2022, addressed to shareholders. Although the text is in Polish, the content describes full-year performance, strategic goals, infrastructure development (pharmaceutical plant), clinical trial preparations, and financial context, which aligns perfectly with the scope of a comprehensive Annual Report (10-K equivalent in structure, though this is likely a local market filing). Since the document is the report itself and not just an announcement of its publication, the classification should be 10-K, which is the standard code for an official yearly report covering full financial performance.
2023-04-20 Polish
Zmiana adresu siedziby PolTREG S.A. i adresu strony internetowej - Content (PL)
Regulatory Filings Classification · 95% confidence The document text, written in Polish, announces a change in the registered office address ('zmiana dotychczasowego adresu siedziby Spółki') and the company's website address. It explicitly states that this information is being provided in a 'raport bieżący' (current report). Since the content is a specific corporate action announcement (change of address/website) and not a comprehensive financial report (like 10-K or IR), it needs to be classified based on the provided definitions. None of the specific codes (like DIV, DIRS, CAP) fit this administrative change perfectly. The most appropriate general category for miscellaneous regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS), as it covers general corporate announcements not covered by other specific codes. The document length is very short (728 chars), suggesting it is a brief announcement, reinforcing the idea that it is not a full report.
2023-03-17 Polish
Zawarcie z Clinmark sp. z o.o. zlecenia na prace przygotowawcze do rozpoczęcia badania klinicznego w projekcie TregVacRMS - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board (Zarząd) of PolTREG S.A. regarding the execution of a specific order (zlecenie) with Clinmark for preparatory work related to a Phase 1/2 clinical trial (TregVacRMS for MS). It details the scope of work, compensation (approx. 116k PLN net), and the timeline (March 2023 to December 2023). This type of announcement, concerning a significant operational contract or development milestone, is typically classified as a general regulatory announcement, especially when it relates to ongoing business operations rather than a standard financial report (like 10-K, IR, or ER). Since it doesn't fit the specific definitions for M&A (TAR), Capital changes (CAP/SHA), Director dealings (DIRS), or Dividend notices (DIV), the most appropriate general category for a significant, non-standard regulatory update is Regulatory Filings (RNS). The document length is short (1452 chars), but it is reporting the event itself, not announcing the publication of a separate, larger report, thus avoiding the RPA classification.
2023-03-16 Polish
Uzupełnienie informacji nt. nowego Członka Zarządu PolTREG S.A. - Content (PL)
Board/Management Information Classification · 98% confidence The document text is a detailed biography and professional history ('pełny życiorys wraz z opisem przebiegu pracy zawodowej') of an individual, Ms. Paulina Kocenko-Merks, who has been appointed to the Management Board ('Powołania na Członka Zarządu'). This content directly relates to changes in senior management personnel. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the Board/Management Information category (MANG). The document is not a general regulatory filing (RNS) or a report itself, but specific personnel information.
2023-03-15 Polish
Powołanie nowego Członka Zarządu PolTREG S.A. - Content (PL)
Board/Management Information Classification · 99% confidence The document text, written in Polish, announces that the Supervisory Board appointed Ms. Paulina Kocenko-Merks as a Management Board Member of PolTREG S.A. effective March 13, 2023. It details her current role (CFO) and previous professional experience. This content directly relates to changes in senior management personnel. According to the definitions, this aligns perfectly with the 'Board/Management Information' category.
2023-03-14 Polish
Zawarcie z Clinmark sp. z o.o. zlecenia na przeprowadzenie badania klinicznego w projekcie PreTREG - Content (PL)
Regulatory Filings Classification · 92% confidence The document is written in Polish and discusses the execution of a contract ('Zlecenie') for conducting a Phase 1/2 clinical trial ('badania klinicznego fazy 1/2') related to a cell therapy project (PreTREG). It details the scope, compensation (approx. 5.3 million EUR), and timeline (ending November 2028). This type of announcement, concerning a significant contract or agreement that impacts the company's operations or future prospects, is typically classified as a general regulatory announcement or a specific material agreement disclosure. Since there is no specific category for 'Material Contract Award' or 'Clinical Trial Update' among the provided codes, and the text is a formal disclosure referencing previous reports ('raport bieżący'), it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, material, non-financial disclosure, or potentially 'LTR' if it were a legal proceeding, but here it is a business agreement. Given the context of ongoing business operations and material agreements, RNS is the most appropriate fallback for a non-standard report disclosure.
2023-02-13 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.